FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

| Vashington, | D.C. 20549 | |
|-------------|------------|--|
|-------------|------------|--|

| STATEMENT | OF CHANGES | IN BENEFICIAL | OWNERSHIP |
|-----------|------------|---------------|-----------|
| | | | |

| OMB APPROVAL | | | | | | | | | |
|--------------------------|-----------|--|--|--|--|--|--|--|--|
| OMB Number: | 3235-0287 | | | | | | | | |
| Estimated average burden | | | | | | | | | |
| hours per response: | 0.5 | | | | | | | | |

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 Instruction 1(b)

| Name and Address of Reporting Person* GRAY MARY ANN | | | | 2. Issuer Name and Ticker or Trading Symbol RAPT Therapeutics, Inc. [RAPT] | | | | | | | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner | | | | | | |
|---|--|---------------|-------------------------------------|--|---|----------|--|---------------|--|------------------|---|--|------------------------------------|--|---|--------------------|---------|
| | • | PEUTICS, INC. | (Middle) | | 3. Date of Earliest Transaction (Month/Day/Year) 03/31/2021 | | | | | | | | Office below) | (give title | | Other (s below) | specify |
| (Street) SOUTH FRANCI | SAN CA | A | 94080 (Zip) | 4. | If Ame | endment, | Date | of Original F | iled (| (Month/D | ay/Year) | 6. Lir | X Form | iled by One | Repo | orting Perso | n |
| | Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned | | | | | | | | | | | | | | | | |
| Date | | | . Transactio Pate Month/Day/Y | Execution Date, | | Code (In | Transaction Disposed Of (D) (Instr. 3, 4 Code (Instr. 5) | | | | Benefici | es For ally (D) Following (I) (| | rm: Direct) or Indirect (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) | | |
| | | | | | | | Code | v | Amount | (A) or (D) Price | | Transac | Transaction(s) (Instr. 3 and 4) | | | (111501.4) | |
| | Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | | | | | | | | | | | | | | | | |
| 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security (Instr. 3) 3. Transaction Date (Month/Day/Year) (Month/Day/Year) 3. Deemed Execution Date, if any (Month/Day/Year) | | | Code | ransaction of Ex ode (Instr. Derivative (M | | | 6. Date Exercisable and Expiration Date (Month/Day/Year) | | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | Beneficial Ownership (Instr. 4) | | |
| | Code V (A) (D) Exercisable Date Expiration Date Title Shares | | | | | | | | | | | | | | | | |
| Stock Option (right to buy) | \$22.2 | 03/31/2021 | | A | | 3,822 | | (2) | 03/ | /30/2031 | Common Stock | 3,822 | \$15.7002 ⁽¹⁾ | 3,822 | | D | |

Explanation of Responses:

- 1. This option was issued to the reporting person pursuant to the Issuer's Amended and Restated Non-Employee Director Compensation Policy in lieu of an annual cash retainers for service on the Board of Directors and committees thereof in the aggregate amount of \$60,000.
- 2. The shares subject to the option vest in four equal quarterly installments on the last day of each fiscal quarter in 2021 with the first installment vesting on March 31, 2021, provided that the reporting person is in service as a director on each such vesting date.

Remarks:

/s/ Rodney Young, Attorney-in-04/02/2021 Fact for Mary Ann Gray

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

POWER OF ATTORNEY

Know all by these presents, that the undersigned hereby constitutes and appoints each of BRIAN WONG, RODNEY YOUNG and MICHAEL TENTA, signing individually, the undersigned's true and lawful attorneys-in-fact and agents to:

- (1) execute for and on behalf of the undersigned, in the undersigned's capacity as an officer, director or beneficial owner of more than 10% of a registered class of securities of RAPT THERAPEUTICS, INC. (the "Company"), Forms 3, 4 and 5 (including any amendments thereto) in accordance with Section 16(a) of the Securities Exchange Act of 1934, as amended (the "Exchange Act") and the rules thereunder and a Form ID, Uniform Application for Access Codes to File on EDGAR;
- (2) do and perform any and all acts for and on behalf of the undersigned that may be necessary or desirable to execute such Forms 3, 4 or 5 or Form ID (including any amendments thereto) and timely file such forms with the United States Securities and Exchange Commission and any stock exchange or similar authority; and
- (3) take any other action of any nature whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion.

The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Exchange Act.

This Power of Attorney shall remain in full force and effect until the earliest to occur of (a) the undersigned is no longer required to file Forms 3, 4 and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, (b) revocation by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact or (c) as to any attorney-in-fact individually, until such attorney-in-fact is no longer employed by the Company or Cooley LLP.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of March 11, 2021.

/s/ Mary Ann Gray Mary Ann Gray, Ph.D.